Volkswagen announces new supervisory board member

Gunnar Kilian Member of the Board of Management of Volkswagen AG
Gunnar Kilian Member of the Board of Management of Volkswagen AG
0Comments

A transition is occurring within the shareholder representatives on the Supervisory Board of Volkswagen Aktiengesellschaft. Marianne Heiß has stepped down from her position effective July 4, 2025. Susanne Wiegand will succeed her starting July 5, 2025. This announcement was made by the company in Wolfsburg.

Marianne Heiß joined the Supervisory Board on February 14, 2018, and also served on its Audit Committee. Hans Dieter Pötsch, Chairman of the Volkswagen Supervisory Board, expressed gratitude for Ms. Heiß’s years of cooperation. He stated that she enriched the board’s work with her expertise in corporate management and strategy, brand work, finance and accounting, as well as environmental, social and governance (ESG) matters.

Susanne Wiegand brings over two decades of experience in leadership roles within international listed and family-owned companies in industries such as defense, engineering and shipbuilding. She is recognized for her expertise in growth strategies, IPOs, transformation and industrial markets, along with risk management, compliance and export control. Ms. Wiegand will chair the Audit Committee of the Supervisory Board.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.